Grand Medical Group

About us

Grand Medical Group AG is a group of pharmaceutical companies specialized in the development, production, registration and introduction into medical practice of modern innovative products based on organic, synthetic and herbal compounds.

read more

10 Kornmarkt Street, CH - 6004 Luzern, Switzerland

info@grandmedicalgroup.ch

+41 415880810

Each vial contains cefotaxime sodium equivalent to 1 g of cefotaxime, powder for solution for injection in vial No 1 with solvent 4 ml in ampoule No 1

PHARMACOLOGIC PROPERTIES

ATC code: J01D A10, Beta-lactam antibiotics, cephalosporins.

Cefotaxime is a third generation broad spectrum bactericidal cephalosporin antibiotic. The bactericidal properties are due to the inhibitory e?ect of cefotaxime on bacterial cell wall synthesis. Unlike ß-lactams such as penicillin and amoxicillin, which are highly susceptible to degradation by ß-lactamase enzymes (produced, for example, nearly universally by S. aureus), cefotaxime boasts the additional bene?t of resistance to ß-lactamase degradation due to the structural con?guration of the cefotaxime molecule. The syn-con?guration of the methoxyimino moiety confers stability against ß-lactamases. Consequently, the spectrum of activity is broadened to include several ß-lactamase-producing organisms (which would otherwise be resistant to ß-lactam antibiotics).

THERAPEUTIC INDICATIONS


1.Cefotaxime is indicated in the treatment of serious infections, either before the infecting organism has been identi?ed or when caused by bacteria of established sensitivity, including
• Osteomyelitis,
• Septicaemia,
• Bacterial endocarditis,
• Meningitis,  
• Peritonitis and other serious bacterial infections suitable for parenteral antibiotic therapy.

2.Cefotaxime may be used for pre-operative prophylaxis in patients undergoing surgical procedures that may be classi?ed as contaminated or potentially so.

LEAFLETS